Kymera's lead pipeline candidate received some good news. Shares of Kymera Therapeutics (KYMR 23.66%) were soaring 18.4% higher as of 11:28 a.m. ET on Tuesday. The big jump came after the clinical-stage biopharmaceutical company announced on Monday that its partner, Sanofi, plans to expand the ongoing phase 2 studies evaluating experimental drug KT-474 in treating two skin conditions: hidradenitis suppurativa and atopic dermatitis. Sanofi opted to expand the phase 2 studies of KT-474 to accelerate the advan ...

The candidate is in phase II studies for hidradenitis suppurativa (HS) and atopic dermatitis (AD). Shares of KYMR have surged 25.5% year to date against the industry's decline of 7.1%. KT-474 (SAR444656) is a first-in-class IRAK4 degrader in development for the treatment of immuneinflammatory diseases with significant patient need, such as hidradenitis suppurativa (HS) and atopic dermatitis (AD). Sanofi informed Kymera about the decision to expand the study after a review of preliminary safety and efficacy ...

WATERTOWN, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in a fireside chat at the UBS Virtual TPD Day on July 15, 2024, at 1:00 p.m. ET. A live webcast of the presentation will be available under "News and Events" in the Investors section of the Company's website at www.kymeratx.com. A re ...

"We are pleased that Sanofi has taken steps to expand these studies, as we are firm believers in the potential for KT-474 to address significant unmet needs with large market potential," said Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics. "This expansion, supported by the results of the interim analysis, is intended to accelerate overall timelines and inform future registrational trials. We look forward to sharing further information as it is available, including trial designs and upd ...

KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin's lymphoma Robust STAT3 knockdown and positive immunomodulatory effect achieved in blood and tumor KT-333 was well-tolerated with Phase 1 dose escalation ongoing and additional data expected in the second half of 2024 WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company a ...

KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin's lymphoma WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today shared new clinical data from its ongoing KT-333 Phase 1 trial. KT333, a first-in-class, potent, highly select ...

WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events: Jefferies 2024 Global Healthcare Conference in New York, NY on June 5 at 11:30 a.m. ET; and Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL on June 11 at ...

Abstract released today highlights safety, pharmacodynamic and clinical response data with additional data to be presented in a poster session on June 1, 2024 WATERTOWN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced new clinical data for KT-253, a first-in-class MDM2 degrader, from its ongoing Phase 1 dose escalation trial ...

KT-621 expected to start Phase 1 in the second half of 2024, with Phase 1 data in the first half of 2025 Additional KT-621 preclinical data was also featured in a poster presentation at Digestive Disease Week The company previously presented data showing its first-in-class oral STAT6 degrader, KT-621, was exquisitely selective for STAT6 over other STATs and fully blocked IL-4/IL-13 functions in key human TH2 cellular assays with picomolar potency that was superior to dupilumab. In addition, at low daily ora ...

KT-333新一期数据展示 - Kymera Therapeutics, Inc.（NASDAQ:KYMR）宣布将在2024年6月13-16日在西班牙马德里举行的欧洲血液学协会（EHA）年会上展示KT-333的新一期数据[1] - KT-333是一种针对STAT3的第一类降解剂，已在特定患者群中展示出临床显著的反应，包括两名cHL患者在DL4获得完全反应，以及CTCL患者在DL2、4和5获得三个部分反应[2] - KT-333在DL1-5的周围血单核细胞中实现了高达97.5%的最大降解，在CTCL肿瘤活检中DL4显示了STAT3、pSTAT3和SOCS3表达的显著减少[3] - KT-333在周围血液和肿瘤中诱导了与对抗PD1敏感性相关的IFN-γ刺激基因签名，表明在KT-333治疗后肿瘤微环境中出现了有利的免疫调节反应[4]